

# CITATION REPORT

List of articles citing

## Cannabis and Pain: A Clinical Review

DOI: 10.1089/can.2017.0017

Cannabis and Cannabinoid Research, 2017, 2, 96-104.

**Source:** <https://exaly.com/paper-pdf/66483855/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
141	The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. <b>2017</b> , 14, 32		41
140	Cannabinoids and Pain: New Insights From Old Molecules. <b>2018</b> , 9, 1259		104
139	Commentary on Liang et al. (2018): The potential impact of medical cannabis on public health with respect to reducing prescription opioid use and associated harm. <b>2018</b> , 113, 2071-2072		1
138	Association of Cannabinoid Administration With Experimental Pain in Healthy Adults: A Systematic Review and Meta-analysis. <b>2018</b> , 75, 1118-1127		35
137	The association between perceived distress tolerance and cannabis use problems, cannabis withdrawal symptoms, and self-efficacy for quitting cannabis: The explanatory role of pain-related affective distress. <b>2018</b> , 85, 1-7		8
136	Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases. <b>2018</b> , 11, 837-842		28
135	The Association Between Cannabis Use and Aberrant Behaviors During Chronic Opioid Therapy for Chronic Pain. <b>2018</b> , 19, 1997-2008		16
134	Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy. <b>2018</b> , 10, 19-28		5
133	Medicinal cannabis: presenting possible treatment modalities for the future. <b>2018</b> , 16, 81-82		
132	Associations of PTSD, chronic pain, and their comorbidity on cannabis use disorder: Results from an American nationally representative study. <b>2019</b> , 36, 1036-1046		10
131	Chronic Pain: Structural and Functional Changes in Brain Structures and Associated Negative Affective States. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	59
130	Cannabis use in active athletes: Behaviors related to subjective effects. <b>2019</b> , 14, e0218998		16
129	Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives. <b>2019</b> , 10, 1284		5
128	The Interaction of Alcohol Use and Cannabis Use Problems in Relation to Opioid Misuse Among Adults with Chronic Pain. <b>2019</b> , 26, 569-575		8
127	The Endocannabinoid System of Animals. <b>2019</b> , 9,		30
126	Cannabinoids and Pain Management: an Insight into Recent Advancements. <b>2019</b> , 7, 208-213		
125	Comparative studies of endocannabinoid modulation of pain. <b>2019</b> , 374, 20190279		11

124	Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis. <b>2019</b> , 233, 181-192		78
123	Role of Cannabinoids and Terpenes in Cannabis-Mediated Analgesia in Rats. <i>Cannabis and Cannabinoid Research</i> , <b>2019</b> , 4, 177-182	4.6	13
122	Cannabinoids in Pain Treatment: An Overview. <b>2019</b> , 20, 107-112		4
121	Potency Analysis of Medical Marijuana Products from New York State. <i>Cannabis and Cannabinoid Research</i> , <b>2019</b> , 4, 195-203	4.6	6
120	Pain Relief as a Motivation for Cannabis Use Among Young Adult Users With and Without Chronic Pain. <b>2019</b> , 20, 908-916		10
119	Medical Marijuana-Induced Tacrolimus Toxicity. <b>2019</b> , 60, 603-605		9
118	Total Phenolic and Flavonoid Content and Biological Activities of Extracts and Isolated Compounds of Pourr. <b>2019</b> , 9,		7
117	Mechanisms and treatment of bone pain in multiple myeloma. <b>2019</b> , 13, 408-416		8
116	Opioid and Cannabis Co-Use among Adults With Chronic Pain: Relations to Substance Misuse, Mental Health, and Pain Experience. <b>2019</b> , 13, 287-294		25
115	A Reciprocal Model of Pain and Substance Use: Transdiagnostic Considerations, Clinical Implications, and Future Directions. <b>2019</b> , 15, 503-528		56
114	Benefits and adverse effects of cannabis use among adults with persistent pain. <b>2019</b> , 67, 223-231		15
113	Natural products as a perspective for cancer pain management: A systematic review. <b>2019</b> , 58, 152766		14
112	Patients' and clinicians' perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary care. <b>2019</b> , 63, 23-28		18
111	Medical cannabis for chronic pain: can it make a difference in pain management?. <b>2020</b> , 34, 95-103		16
110	Cannabinoid Receptor Type 1 and Its Role as an Analgesic: An Opioid Alternative?. <b>2020</b> , 16, 106-119		5
109	Is there a relationship between cannabis use problems, emotion dysregulation, and mental health problems among adults with chronic pain?. <b>2020</b> , 25, 742-755		6
108	A Preliminary Study of Associations between Discomfort Intolerance, Pain Severity/Interference, and Frequency of Cannabis Use among Individuals with Chronic Pain. <b>2020</b> , 28, 76-81		6
107	A Comprehensive Patient and Public Involvement Program Evaluating Perception of Cannabis-Derived Medicinal Products in the Treatment of Acute Postoperative Pain, Nausea, and Vomiting Using a Qualitative Thematic Framework. <i>Cannabis and Cannabinoid Research</i> , <b>2020</b> , 5, 73-80	4.6	1

106	Investigation of the Involvement of the Endocannabinoid System in TENS-Induced Antinociception. <b>2020</b> , 21, 820-835	1
105	Endogenous opioid and cannabinoid systems contribute to antinociception produced by administration of NSAIDs into the insular cortex of rats. <b>2020</b> , 131, 110722	2
104	Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. <b>2020</b> , 16, 645-660	62
103	Medical marijuana and clinical trials. <b>2020</b> , 243-260	0
102	Daring discourse - yes: practical considerations for cannabis use in the perioperative setting. <b>2020</b> , 45, 524-527	0
101	Opioid Misuse and the Availability of Medical Marijuana Through Dispensaries. <b>2020</b> , 81, 489-496	1
100	Understanding the Medical Chemistry of the Cannabis Plant is Critical to Guiding Real World Clinical Evidence. <b>2020</b> , 25,	8
99	No Evidence of Altered Reactivity to Experimentally Induced Pain Among Regular Cannabis Users. <b>2020</b> , 36, 589-593	3
98	In our war against the opioid epidemic, could 'weed' be a winner?. <b>2020</b> , 20, 423-429	1
97	Motivations and expectations for using cannabis products to treat pain in humans and dogs: a mixed methods study. <b>2020</b> , 2, 36	2
96	Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors. <b>2020</b> , 56,	29
95	Canadian clinical practice guidelines for the use of plant-based cannabis and cannabinoid-based products in the management of chronic non-cancer pain and co-occurring conditions: protocol for a systematic literature review. <b>2020</b> , 10, e036114	4
94	Pain interference and catastrophizing are not associated with polysubstance use among treatment-seeking patients with substance use disorders and chronic pain. <b>2020</b> , 46, 604-612	3
93	The Role of the Cannabinoid System in Pain Control: Basic and Clinical Implications. <b>2020</b> , 24, 35	3
92	Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression. <b>2020</b> , 15, 801-829	17
91	Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3 20
90	Cannabinoids in the Treatment of Back Pain. <b>2020</b> , 87, 166-175	5
89	Comparative Evaluation of Combinatory Interaction between Endocannabinoid System Compounds and Poly-L-lysine against Growth and Biofilm Formation. <b>2020</b> , 2020, 7258380	6

88	Cannabis Use and Low-Back Pain: A Systematic Review. <i>Cannabis and Cannabinoid Research</i> , <b>2020</b> , 5, 283-289	6
87	Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy. <b>2020</b> , 56,	8
86	Clinical uses of cannabis and cannabinoids in the United States. <b>2020</b> , 411, 116717	25
85	Does Cannabis Dependence Add on to the Neurocognitive Impairment Among Patients With Opioid Dependence? A Cross-Sectional Comparative Study. <b>2020</b> , 29, 120-128	3
84	The relationships between chronic pain and changes in health with cannabis consumption patterns. <b>2020</b> , 76, 102657	3
83	Positive Allosteric Modulation of CB Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. <b>2020</b> , 13, 54	24
82	Perioperative Pain Management Strategies in the Age of an Opioid Epidemic. <b>2020</b> , 35, 347-352	0
81	Potential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus. <b>2020</b> , 15, e0231583	9
80	A Network Pharmacology Approach to Identify Potential Molecular Targets for Cannabidiol's Anti-Inflammatory Activity. <i>Cannabis and Cannabinoid Research</i> , <b>2021</b> , 6, 288-299	4.6 3
79	Characterization of substance use among underrepresented sexual and gender minority participants in The Population Research in Identity and Disparities for Equality (PRIDE) Study. <b>2021</b> , 42, 104-115	6
78	Use of Medical Cannabis to Treat Traumatic Brain Injury. <b>2021</b> , 38, 1904-1917	3
77	Perioperative Pain and Addiction Interdisciplinary Network (PAIN): consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users by a modified Delphi process. <b>2021</b> , 126, 304-318	10
76	Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors. <b>2021</b> , 61, 441-463	17
75	Adjuvant Treatments for CRPS. <b>2021</b> , 149-177	
74	Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses. <b>2021</b> , 13,	21
73	The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review. <b>2021</b> , 19, 402-432	2
72	Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model. <b>2021</b> , 73, 820-827	2
71	Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials. <b>2021</b> , 22, 141-149	7

70	Endocannabinoid system: Role in blood cell development, neuroimmune interactions and associated disorders. <b>2021</b> , 353, 577501		2
69	Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles. <b>2021</b> , 221, 108648		2
68	Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada. <i>BMC Public Health</i> , <b>2021</b> , 21, 843	4.1	5
67	Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. <b>2021</b> , 10, 109-118		4
66	Delivering therapeutic cannabinoids via skin: Current state and future perspectives. <b>2021</b> , 334, 427-451		10
65	Cannabinoids and chronic pelvic pain in women: Focus on endometriosis. 228402652110112		3
64	Conversion Characteristics of Some Major Cannabinoids from Hemp ( L.) Raw Materials by New Rapid Simultaneous Analysis Method. <b>2021</b> , 26,		3
63	The Treatment of Painful Diabetic Neuropathy. <b>2021</b> ,		3
62	The Role of Organic Small Molecules in Pain Management. <b>2021</b> , 26,		2
61	Cannabis and pain: a scoping review. <b>2021</b> ,		2
60	Potential Role of Cannabidiol on Sports Recovery: A Narrative Review. <b>2021</b> , 12, 722550		4
59	Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine. <b>2021</b> , 10,		3
58	Innovative and emerging applications of cannabis in food and beverage products: From an illicit drug to a potential ingredient for health promotion. <b>2021</b> , 115, 31-41		5
57	Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. <b>2021</b> , 26,		1
56	Cannabidiol-based natural health products for companion animals: Recent advances in the management of anxiety, pain, and inflammation. <b>2021</b> , 140, 38-46		1
55	Cannabinoid and Opioid Use Among Total Joint Arthroplasty Patients: A 6-Year, Single-Institution Study. <b>2021</b> , 44, e101-e106		2
54	Clinical Conditions and Prescription Drug Utilization among Early Medical Marijuana Registrants in Florida. <b>2021</b> , 53, 185-194		1
53	Fibromyalgia Syndrome and Sleep. <b>2021</b> , 205-221		

52	The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. <b>2020</b> , 24, 1505-1516		20
51	Effects of cannabinoid administration for pain: A meta-analysis and meta-regression. <b>2019</b> , 27, 370-382		24
50	Cannabis and cannabinoids in cancer pain management. <b>2020</b> , 14, 87-93		8
49	A Scoping Review on Clinical Trials of Pain Reduction With Cannabis Administration in Adults. <b>2020</b> , 12, 344-351		7
48	Up-regulation of heme oxygenase-1 expression and inhibition of disease-associated features by cannabidiol in vascular smooth muscle cells. <b>2018</b> , 9, 34595-34616		20
47	Evidence of Cannabinoids in Pain. <b>2020</b> , 171-183		
46	Demographics, Perceptions, and Use of Medical Marijuana among Patients in Florida. <b>2021</b> , 4, 13-20		5
45	Medicinal cannabis: Pharmaceutical forms and recent analytical methodologies. <b>2020</b> , 31-63		1
44	Pain: Physiologic background and therapeutic Consequences. <b>2020</b> , 13, 1		1
43	Chronic migraine caused a higher rate of tendency to cannabinoid agonist compared to morphine. <b>2020</b> , 91, e2020185		
42	The terpenes camphene and alpha-bisabolol inhibit inflammatory and neuropathic pain via Cav3.2 T-type calcium channels. <b>2021</b> , 14, 166		2
41	A narrative review of molecular mechanism and therapeutic effect of Cannabidiol (CBD).. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2022</b> ,	3.1	12
40	EXPLORING THE EFFICACY AND SAFETY OF CANNABIS IN THE MANAGEMENT OF FIBROMYALGIA. <i>International Journal of Current Pharmaceutical Research</i> , 27-30	0.2	0
39	Approaches to studying injury-induced sensitization and the potential role of an endocannabinoid transmitter.. <i>Journal of Comparative Physiology A: Neuroethology, Sensory, Neural, and Behavioral Physiology</i> , <b>2022</b> , 208, 313	2.3	1
38	An overview of the use and misuse/abuse of opioid analgesics in different world regions and future perspectives.. <i>Pain Management</i> , <b>2022</b> ,	2.3	0
37	Stratégies face à la crise des opioïdes : analyse des revues systématiques. <i>Drogues, Santé Et Société</i> <b>2021</b> , 19, 103	0.1	
36	Association between cannabis use and physical health problems in Norwegian adolescents: a cross-sectional study from the youth survey Ungdata.. <i>BMC Public Health</i> , <b>2022</b> , 22, 661	4.1	1
35	A perspective review of cannabis use and sexual offenses.. <i>Behavioral Sciences and the Law</i> , <b>2022</b> ,	1.9	

34	Cannabinoid-Based Innovative Prophylactic and Therapeutic Interventions for Neuropathic Pain and Migraine. <b>2022</b> , 101-112		
33	Cannabis and Organ Damage: A Focus on Pancreatitis (to Include Different Scenarios). <b>2022</b> , 1-11		
32	Effect of Fatty Acid Amide Hydrolase Inhibitor URB597 on Orofacial Pain Perception in Rats.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	0
31	Advances in the management of fibromyalgia: what is the state of the art?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2022</b> , 1-11	4	
30	Cannabis and Cannabinoids in the Perioperative Period.. <i>Anesthesia and Analgesia</i> , <b>2022</b> ,	3.9	0
29	Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation.. <i>Cell</i> , <b>2022</b> ,	56.2	5
28	Serotonin mediates stress-like effects on responses to non-nociceptive stimuli in Hirudo.. <i>Journal of Experimental Biology</i> , <b>2022</b> ,	3	
27	Optimization of the Decarboxylation of Cannabis for Commercial Applications. <i>Industrial &amp; Engineering Chemistry Research</i> ,	3.9	1
26	Systematic reviews of randomized controlled trials of cannabinoid products in chronic pain conditions and for symptoms associated with multiple sclerosis: what do they tell us?. <i>Expert Review of Clinical Pharmacology</i> ,	3.8	
25	Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis.		
24	Cannabis-based medicinal products: a clinical guide. <b>2022</b> , 18, 170-174		
23	Peroxisome proliferator-activated receptor gamma agonist ELB00824 suppresses oxaliplatin-induced pain, neuronal hypersensitivity, and oxidative stress. <b>2022</b> , 218, 109233		
22	Validation of the Motivational Inventory Underlying Substance Use Engagement (MI-USE). 1-12		0
21	Practical Considerations for the Use of Cannabis in Cancer Pain Management—What a Medical Oncologist Should Know. <b>2022</b> , 11, 5036		0
20	Cannabis and Organ Damage: A Focus on Pancreatitis (to Include Different Scenarios). <b>2022</b> , 1343-1352		0
19	Cannabinoids: Legal aspects, pharmacology, phytochemistry, probable targets from biological system, and therapeutic potential. <b>2022</b> , 14, 127		0
18	Functional consequences of short-term exposure to opioids versus cannabinoids in nonhuman primates. <b>2023</b> , 223, 109328		0
17	A reliable quantitative method for determining CBD content and release from transdermal patches in Franz cells.		1



- 16 Association of cannabis and/or opioid with quality of life and healthcare utilization in patients with chronic pain. 3, ○
- 15 Towards dsRNA -integrated protection of medical Cannabis crops: considering human safety, recent- and developing RNAi methods, and research inroads. ○
- 14 Past Cannabis Use, Health-Related Worry, and Beliefs About Perceived Benefits of Cannabis Among American Indians/Alaska Natives. ○
- 13 The C4EB study▯ransvamiX (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study. **2022**, 17, e0277512 ○
- 12 Prevention, Practice, and Policy: Older US Veterans▯Perspectives on Cannabis Use. ○
- 11 ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. rapm-2022-104013 ○
- 10 The antinociceptive activity and mechanism of action of cannabigerol. **2023**, 158, 114163 ○
- 9 Intimate partner violence, substance use, and health comorbidities among women: A narrative review. 13, ○
- 8 Microglial Cannabinoid CB2 Receptors in Pain Modulation. **2023**, 24, 2348 ○
- 7 Measurement of ▯THC and metabolites in the brain and peripheral tissues after intranasal instillation of a nanoformulation. **2023**, 5, ○
- 6 Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study. **2023**, 23, 281-295 ○
- 5 A national population-based study of cannabis use and correlates among U.S. veterans prescribed opioids in primary care. **2023**, 23, ○
- 4 Marijuana Policies in Drug Treatment Courts. 002204262311637 ○
- 3 Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. ○
- 2 Use of Marijuana to Promote Well-Being: Effects of Use and Prohibition in the Daily Lives of Brazilian Adults. **2023**, 17, 117822182311624 ○
- 1 A cross-sectional survey of prospective healthcare professionals' knowledge, attitudes and perceptions of medical Cannabis. **2023**, 100275 ○